Engflag

Bo En

Quick links to important sections

Bo En

Bo En_EN

Method of action: Antitumour

Treatment option: Carcinoma, Small Cell Lung Cancer, Cancer, Cancer,Lung, Cancer,Cervix

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bo En

Quick Facts

Property Description
Active ingredient Topotecan Hydrochloride
Form Lyophilized Powder for Injection, Solution for Infusion
Pharmacological class Antineoplastic Agent, Topoisomerase I Inhibitor
General purpose Systemic control of malignant human tumors
Origin Semisynthetic Derivative (of camptothecin)

What Type of Medicine is Bo En and Its Active Compound?

Bo En is a specialized, semisynthetic antineoplastic agent developed for the systemic management of certain malignancies, belonging to the pharmacological class of Topoisomerase I Inhibitors. The medication's active ingredient is Topotecan Hydrochloride, which is a unique derivative of the naturally occurring camptothecin alkaloid. This specific origin and structure are clinically recognized for providing a distinct mechanism of action within chemotherapy protocols. This compound is the core component found in various formulations and is characterized as a powerful chemotherapeutic agent whose purpose is to target and disrupt the fundamental processes of cellular replication. Topotecan is recognized as an important component in the treatment landscape for cancer patients.

Bo En’s Purpose and How Its Composition is Presented

The primary purpose of Bo En is to exert controlled cytotoxic effects on malignant cells by selectively interfering with the DNA management system, ultimately helping to manage the progression of aggressive diseases. As a Topoisomerase I Inhibitor, its mechanism is supported by pharmacological research that details how it causes irreparable damage to the cancer cell's genetic material, leading to programmed destruction known as apoptosis. Topotecan is characterized as a medicine indicated for specific cancer treatments, which defines its classification and use profile. The product is typically presented for clinical use either as a sterile, ready-to-use solution for infusion or a lyophilized powder that requires reconstitution prior to delivery. This presentation is essential for delivery via intravenous infusion, which ensures the active ingredient is precisely and systemically distributed to target human tumors.

Regulatory References

  1. National Cancer Institute

What side effects are possible with Bo En?

Possible side effects and safety information

The official safety profile for Bo En (Topotecan) is defined by classifications from government regulatory documents, focusing primarily on dose-limiting toxicities and specific constraints for use.

Adverse Reaction Scope

The primary concern is Myelosuppression (bone marrow suppression), which is categorized as Very Common (1/10). This leads to reduced blood cell counts, specifically neutropenia, anemia, and thrombocytopenia. The nadir (lowest point) for neutrophil counts typically occurs around a median of 12 to 15 days after administration.

Very Common non-hematologic effects, classified across the Gastrointestinal and General Disorders System-Organ Classes, include nausea, vomiting, diarrhea, fatigue, asthenia, and alopecia (hair loss). Less common effects are formally classified, with Interstitial Lung Disease (ILD) being designated as Rare (1/10,000).

Serious Adverse Reactions

The documented serious adverse reactions include severe myelosuppression (which may lead to life-threatening complications like sepsis or hemorrhage), Febrile Neutropenia, and Neutropenic Enterocolitis. Fatal cases of ILD have also been reported in regulatory warnings.

Safety Constraints and Specific Populations

Bo En is contraindicated in patients with a history of severe hypersensitivity reactions, pre-existing severe bone marrow depression, and during pregnancy or lactation. The medicine is not recommended for use in patients with severe hepatic or severe renal impairment due to insufficient clinical data. Official labels note that diarrhea has been observed more frequently in the geriatric population.

Regulatory Safety Summary

This regulatory structure establishes myelosuppression as the dominant, anticipated safety characteristic, necessitating continuous observation. The profile systematically maps the full spectrum of possible effects across body systems using official frequency tiers and details specific critical Serious Adverse Reactions, while establishing strict constraints for use in specific populations with organ impairment or reproductive potential.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Bo En

Overdose scope

Category Regulatory Statement
Documented overdose presentations The primary complication of overdosage is severe myelosuppression. Other presentations include mucositis, general gastrointestinal toxicity, and skin toxicity.
Physiological systems affected Hematologic system (neutropenia, thrombocytopenia, anemia), Gastrointestinal system, and Hepatic system (elevated enzymes).
Dose-related or exposure-related factors Overdoses of up to 10-fold the recommended dose have been reported. Exceeding a single dose of 4 mg intravenously is generally cautioned against.
Population-specific overdose notes Patients with moderate renal impairment (CrCl of 20 to 39 mL/min) have reduced drug clearance, increasing the risk of toxicity.
Emergency-response statements If an overdose is suspected, the guidance requires close monitoring for myelosuppression and institution of supportive-care measures as appropriate.
When immediate medical help is required Immediate medical care must be sought if an overdose is suspected, or if signs of severe infection, bleeding, or abdominal symptoms occur.

Overdose classifications (high-level)

Category Regulatory Statement
Severity classification Severe myelosuppression is defined as the primary complication. Life-threatening outcomes include fatal sepsis and fatal neutropenic colitis (typhlitis).
Regulatory basis Information derived from government-authorized documents (FDA Prescribing Information, EMA SmPC).
Overdose-context constraints No specific antidote is known for overdosage; therefore, management is strictly symptomatic and supportive.

Resulting overdose structure

Official overdose statements:

  • The primary complication documented following overdosage is severe myelosuppression, leading to hematologic toxicities including Grade 4 neutropenia and thrombocytopenia.
  • Consequences of severe toxicity include the risk of sepsis and fatal neutropenic colitis, which are associated with the profound reduction in white blood cells.
  • Immediate medical care is mandated if an overdose is suspected, or if severe symptoms such as fever, severe bleeding, or signs of lung toxicity are noted.
  • Management of overdosage is symptomatic and supportive, and close patient monitoring is required.

Connection to the overall overdose profile:

Regulatory documents define the overdose profile for Bo En based on its dose-limiting toxicity, which is severe myelosuppression, explicitly classifying this as the primary danger following overexposure. This risk directly links to the mandatory requirement to seek immediate medical care, thereby establishing the high-risk nature of the overdose. Since no specific antidote is available, the regulatory structure mandates that the primary focus of emergency management must be on administering general supportive-care measures.

Therapeutic Uses of Bo En

The medication Bo En is used for symptomatic support across three main domains where symptoms interfere with daily functioning. The medication is indicated for situations involving certain distressing symptoms.

Bo En is relevant for easing balance-related issues, such as vertigo (a spinning sensation) and general dizziness. It helps address symptom clusters that may become intense or disruptive due to conditions where functional stability becomes affected. This helps manage symptoms that interfere with daily comfort, and contributes to easing the overall symptom load during periods of heightened symptoms.

This medication is also used to address gastrointestinal distress, namely nausea (feeling sick) and vomiting, when these symptoms occur alongside balance disturbances.

Key Use: Managing Motion-Related Symptoms

Bo En is commonly used to provide symptomatic assistance and support for acute or recurrent episodes of motion sickness that are triggered by movement during travel (car, boat, or plane). It is applied in scenarios where additional management of discomfort is required, and may assist with maintaining functional stability, providing supportive relief when symptoms interfere with routine activities.

“It is commonly used across conditions presenting with acute episodes, offering symptomatic relief that supports general well-being during symptomatic phases.”

Eligibility and Restrictions for Use

Bo En (Topotecan Hydrochloride) is a highly specialized medicine with strict eligibility rules defined by regulatory authorities like the FDA and EMA.

Contraindicated Populations

Use is absolutely prohibited in patients with a history of severe hypersensitivity reactions to Topotecan or any of its components. It is also contraindicated for patients entering treatment with severe bone marrow depression, defined specifically by a baseline neutrophil count less than 1.5 imes 10^9/ L or a platelet count less than 100 imes 10^9/ L. The medicine is also strictly contraindicated during breastfeeding.

Population Restrictions

Eligibility Status Population or Condition
Not Recommended Children and adolescents (Pediatric use is not established).
Not Recommended Patients with severe renal impairment (creatinine clearance < 20 mL/min).
Conditional Use Patients with moderate renal impairment (20 to 39 mL/min) require mandatory dose adjustment.
Conditional Use Women who are pregnant or may become pregnant are not recommended to use this medicine due to potential fetal harm, and effective contraception is required.

Older adults may use the medicine without a mandatory dose change based on age alone, but monitoring for underlying kidney impairment is required.

What should I know about interactions with other medicines?

This section outlines the officially documented interaction patterns for Bo En (Topotecan Hydrochloride) found in regulatory documents, focusing on pharmacodynamic and pharmacokinetic constraints.

Documented Interaction Patterns

Interacting Agent / Class Official Description of Interaction Restriction / Constraint
Cisplatin (Chemotherapeutic Agent) Causes greater myelosuppression; associated with reduced topotecan clearance [FDA/EMA]. Combination use is restricted to patients with serum creatinine le 1.5 mg/dL [FDA].
G-CSF (Hematopoietic Growth Factor) Concomitant use can prolong neutropenia [FDA]. Must not be initiated until 24 hours after completion of Bo En treatment [FDA].
P-gp or BCRP Inhibitors Expected to increase systemic exposure of the drug [FDA]. Co-administration is avoided with the oral formulation [FDA].

Other Pharmacokinetic Notes

Bo En does not exhibit an inhibitory effect on human cytochrome P450 (CYP) enzymes. Pharmacokinetic studies indicated that co-administration with Granisetron, Ondansetron, Morphine, or Corticosteroids did not significantly affect the total topotecan concentration. There are no formally documented interaction statements with food, alcohol, or herbal products in the primary regulatory labels.

The regulatory profile defines the drug’s interaction structure by imposing specific timing rules and patient-status restrictions to manage the documented risks of increased toxicity and altered systemic exposure.

Mechanism of Action

Targeting the Endothelin-1 Signaling Pathway

Bo En (Bosentan) acts by engaging a mechanism of dual receptor antagonism, blocking both the ET A and ET B receptor subtypes found primarily on cells within the pulmonary vascular walls. This targeted action interferes with the Endothelin-1 (ET-1) pathway, which is a major regulator of excessive vasoconstriction and abnormal cell proliferation in the pulmonary arteries.

Modulating Vascular Tone and Structure

The drug modifies early molecular steps by competitively preventing ET-1 from binding to its receptors. This interaction results in the suppression of signaling sequences that initiate chronic vessel narrowing and thickening, a process known as vascular remodeling. This mechanism produces the physiological change of dilation of pulmonary blood vessels, directly resulting in a reduction in vascular resistance within the lungs.

System-Level Physiological Consequence

The reduction in pulmonary vascular resistance and corresponding decrease in pulmonary arterial pressure subsequently reduces the mechanical workload on the right ventricle of the heart, modulating the strain on the cardiovascular system.

Dosage and Administration Information

How Bo En is Used

Bo En (Topotecan Hydrochloride) is administered according to established cyclical protocols to ensure standardized systemic delivery of the antineoplastic agent. The medicine is primarily delivered via intravenous (IV) infusion in specialized healthcare settings, though an oral capsule form is used for certain indications in some regions.

Official Administration Regimens and Frequency

Feature Official Labeled Instruction
Route & Infusion Duration Administered by IV infusion over 30 minutes; capsules are swallowed whole.
Standard Adult Dose (Monotherapy) 1.5 mg/m^2 (per Body Surface Area) daily.
Treatment Schedule Dosing occurs on 5 consecutive days, followed by a 16-day rest period, completing one 21-day treatment cycle.

Administration Conditions and Adjustments

The dosage is mathematically determined based on the patient's Body Surface Area (BSA). For patients with documented moderate renal impairment (creatinine clearance 20 to 39 mL/min), the monotherapy dose is reduced to 0.75 mg/m^2 daily.

Before administration, the lyophilized powder form requires reconstitution and dilution in approved IV solutions (e.g., 0.9% Sodium Chloride) to ensure proper systemic delivery. Treatment cycles can only be initiated if the patient's baseline blood counts (neutrophil count ge 1,500/mm^3 and platelet count ge 100,000/mm^3) meet the minimum clinical parameters. If an oral dose is vomited, instructions state to skip that dose and resume the schedule on the next day.

Recent Clinical Evidence

Research evidence / Overview of Studies for Bo En (Topotecan)

Evidence for Use in Relapsed Small Cell Lung Cancer (SCLC)

Research exploring Bo En was studied for use as a treatment following initial chemotherapy failure, known as second-line therapy. The studies primarily included Randomized Controlled Trials (RCTs) that evaluated the medicine against a specific control group. The populations evaluated were adults whose SCLC had returned after an initial regimen that included platinum-based treatment (platinum-sensitive disease). Researchers examined and monitored high-level outcomes related to systemic or functional imbalance, including Overall Survival (OS) and Progression-Free Survival (PFS), as well as the measured size of tumors and patient-reported outcomes describing perceived discomfort. The research so far shows that results apply only to the populations studied.

Evidence for Use in Metastatic Carcinoma of the Ovary

Research on Bo En for advanced or recurrent ovarian carcinoma was evaluated in Randomized Controlled Trials (RCTs) and Systematic Reviews that explored the drug's profile following the failure of first-line or subsequent therapies. Studies primarily involved adult women, including those whose cancer was classified as either platinum-sensitive or platinum-resistant/refractory. The key outcomes that research examined were measurements of Overall Survival, Progression-Free Survival, and Objective Response Rate to characterize tumor behavior during the study period. Studies observed varied patterns when evaluated against certain other single-agent therapies.

What is Still Uncertain About Bo En’s Research Profile

Research indicates that long-term effects are not fully established for all indications. The evidence quality varies across studies, and some sample sizes were modest in early phase research, indicating where the body of evidence may be limited. Comparative evidence is lacking for certain pairings when trying to place the medicine alongside all currently available treatment options in network analyses. Furthermore, research on the profile of Bo En as a single agent for cervical cancer remains limited, as the primary data supports the combination use with Cisplatin.

Key Studies & References

  1. Topotecan for second-line chemotherapy of small cell lung cancer: a systematic review
  2. Topotecan for the treatment of recurrent and metastatic carcinoma of the cervix

How should Bo En be stored and disposed of?

Storage and Disposal of Bo En (Topotecan Hydrochloride)

Storage Requirement Official Condition
Unopened Vials Store at Controlled Room Temperature (20 C to 25 C) and protect from light in the original carton.
Prepared Solution Use immediately after reconstitution; the diluted solution is stable for 24 hours at 20 C to 25 C.

Handling and Disposal Instructions

Bo En is officially classified as a cytotoxic drug and the handling and disposal must strictly adhere to specific regulatory requirements. This mandates that all unused product remaining in the single-use vial or the diluted solution after 24 hours must be discarded immediately. Personnel must follow applicable special handling and disposal procedures for cytotoxic and hazardous medicinal product waste as dictated by local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagChina

Equivalent of Bo En found in:

A-Z Index: